Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,358.40GBp
19 Jan 2018
Change (% chg)

5.20 (+0.38%)
Prev Close
1,353.20
Open
1,351.40
Day's High
1,362.00
Day's Low
1,351.40
Volume
4,181,643
Avg. Vol
10,969,443
52-wk High
1,724.50
52-wk Low
1,270.00

Select another date:

Fri, Jan 12 2018

BRIEF-GSK Receives FDA Approval For Expanded Indication For Fluarix

* GSK RECEIVES FDA APPROVAL FOR EXPANDED INDICATION FOR FLUARIX® QUADRIVALENT (INFLUENZA VACCINE) FOR PERSONS 6 MONTHS AND OLDER Source text for Eikon: Further company coverage:

BRIEF-GSK CEO Says No Expected Dividend Increase In Near Term

* GSK CEO SAYS WILL TAKE TIME TO BUILD REIMBURSEMENT FOR SHINGRIX SHINGLES VACCINE

BRIEF-Glaxosmithkline 9-Month Consol Profit rises

* Q3 CONSOL NET PROFIT EGP 131.1 MILLION VERSUS EGP 103.7 MILLION YEAR AGO

GlaxoSmithKline boosts stake in Saudi Arabia unit

DUBAI, Dec 18 British drugmaker GlaxoSmithKline (GSK) said on Monday it has boosted its stake in its Saudi Arabian unit to 75 percent as it seeks to benefit from the kingdom's plan to transform the economy and raise local manufacturing of pharmaceutical products.

BRIEF-GlaxoSmithkLine Acquires Further 26 Pct Stake In Glaxo Saudi Arabia

* ACQUIRES ADDITIONAL 26 PERCENT STAKE IN GLAXO SAUDI ARABIA LIMITED‍​

BRIEF-Glaxosmithkline Submits Regulatory Application For Single-Dose Tafenoquine For Treatment Of Plasmodium Vivax Malaria

* SUBMITS REGULATORY APPLICATION FOR SINGLE-DOSE TAFENOQUINE FOR TREATMENT OF PLASMODIUM VIVAX MALARIA TO AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION​

BRIEF-Glaxosmithkline Posts H1 Consol Profit

* H1 CONSOL NET PROFIT EGP 103.9 MILLION VERSUS LOSS OF EGP 34.6 MILLION YEAR AGO‍​

BRIEF-Egypt's Glaxosmithkline Posts H1 Standalone Profit

* H1 STANDALONE NET PROFIT EGP 101.7 MILLION VERSUS LOSS OF EGP 31.7 MILLION YEAR AGO

BRIEF-Glaxosmithkline Says ‍New Data From Phase III Clinical Study Supports Safety And Efficacy

* ‍NEW DATA FROM A PHASE III CLINICAL STUDY SUPPORTS SAFETY AND EFFICACY OF SHINGRIX IN PREVENTING SHINGLES​

Australian watchdog takes GlaxoSmithKline, Novartis units to court

The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.

Select another date: